Florian Naudet

2 months ago | telepolis.de | Florian Naudet

Psychedelika erleben ein Comeback in der Psychiatrie. Australien hat MDMA und Psilocybin bereits zugelassen. Die Risiken werden jedoch oft unterschätzt, meint unser Gastautor. Psychedelische Substanzen – von Esketamin (einem Ketamin-Derivat) und Psilocybin (dem Wirkstoff halluzinogener Pilze) bis hin zu MDMA –, die in den 1970er Jahren in Vergessenheit geraten waren, werden heute wieder als potenzielle Therapien für schwere psychiatrische Erkrankungen angesehen.

Dec 11, 2024 | journals.plos.org | Florian Naudet

Loading metrics Open Access Community Page The Community Page is a forum for organizations and societies to highlight their efforts to enhance the dissemination and value of scientific knowledge. See all article types» ? This is an uncorrected proof. Citation: Vinatier C, Kozula M, Van den Eynden V, Caquelin L, Roubik H, Stegeman I, et al. (2024) Public engagement with research reproducibility. PLoS Biol 22(12): e3002953.

Nov 25, 2024 | theconversation.com | Florian Naudet

Le MDMA, la psilocybine issue de champignons hallucinogènes, un dérivé de kétamine ou d’autres « psychédéliques » sont désormais autorisés dans certains pays contre la dépression ou le syndrome de stress post-traumatique, en association avec des psychothérapies. Une analyse des données montre que ces nouveaux traitements sont mis sur le marché malgré des niveaux de preuve insuffisants.

Apr 22, 2024 | bmcmedresmethodol.biomedcentral.com | Clara Locher |Florian Naudet |Hervé Léna |Constant Vinatier |Loïc Fin |Anne Sophie Alix-Doucet | +1 more

The dissemination of clinical trial results is an important scientific and ethical endeavour. This survey of completed interventional studies in a French academic center describes their reporting status. We explored all interventional studies sponsored by Rennes University Hospital identified on the French Open Science Monitor which tracks trials registered on EUCTR or clinicaltrials.gov, and provides an automatic assessment of the reporting of results. For each study, we ascertained the actual reporting of results using systematic searches on the hospital internal database, bibliographic databases (Google Scholar, PubMed), and by contacting all principal investigators (PIs). We describe several features (including total budget and numbers of trial participants) of the studies that did not report any results. The French Open Science Monitor identified 93 interventional studies, among which 10 (11%) reported results. In contrast, our survey identified 36 studies (39%) reporting primary analysis results and an additional 18 (19%) reporting results for secondary analyses (without results for their primary analysis). The overall budget for studies that did not report any results was estimated to be €5,051,253 for a total of 6,735 trial participants. The most frequent reasons for the absence of results reported by PIs were lack of time for 18 (42%), and logistic difficulties (e.g. delay in obtaining results or another blocking factor) for 12 (28%). An association was found between non-publication and negative results (adjusted Odds Ratio = 4.70, 95% Confidence Interval [1.67;14.11]). Even allowing for the fact that automatic searches underestimate the number of studies with published results, the level of reporting was disappointingly low. This amounts to a waste of trial participants' implication and money. Corrective actions are needed. https://osf.io/q5hcs

Jan 11, 2024 | inria.hal.science | Florian Naudet |Chirag Patel |Nicholas DeVito |Gérard Le Goff

Article Dans Une Revue BMJ - British Medical Journal Année : 2024 Improving the transparency and reliability of observational studies through registration Fichier principal RegistrationOBS_NO_TRACKED_CHANGES.pdf (516.66 Ko) Télécharger le fichier Origine : Fichiers produits par l'(les) auteur(s) Commentaire : ACCEPTED MANUSCRIPT / CLEAN COPY hal-04387187 , version 1 (11-01-2024) Florian Naudet, Chirag Patel, Nicholas Devito, Gérard Le Goff, Ioana Cristea, et al.. Improving the transparency...